Skip to main
AIM
AIM logo

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech Inc. has demonstrated a strong positive trajectory in recent clinical studies, particularly with Ampligen, which shows potential as a treatment for multiple cancers and post-COVID conditions. Initial findings from the Phase 2 studies, including those focused on colorectal cancer and post-COVID conditions, have been promising, suggesting further positive data could act as significant catalysts for the company's stock. The company's innovative approach to addressing unmet medical needs in oncology and viral disease therapy positions AIM ImmunoTech favorably in the immuno-pharmaceutical sector.

Bears say

AIM ImmunoTech Inc. reported a net loss of $3.3 million, translating to an earnings per share (EPS) of $(1.57), which significantly missed both company and consensus estimates. The company faces substantial risks impacting its financial outlook, including balance sheet and liquidity challenges, the potential failure of key product candidates in clinical trials, and difficulties related to regulatory approvals and commercialization. Additionally, macroeconomic factors, investor sentiment toward biotech investments, and shifts in healthcare priorities pose further threats that could adversely affect AIM ImmunoTech's stock performance.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.